MDMA-Assisted Psychotherapy

Our highest priority project is funding clinical trials of 3,4-methylenedioxymethamphetamine (MDMA) as a tool to assist psychotherapy for the treatment of posttraumatic stress disorder (PTSD).

We have also sponsored completed clinical trials of MDMA-assisted psychotherapy for anxiety associated with life-threatening illness, and MDMA-assisted psychotherapy for social anxiety in autistic adults.

LSD-Assisted Psychotherapy

MAPS has completed the first double-blind, placebo-controlled study of the therapeutic use of LSD in human beings since the early 1970s.

Ibogaine Therapy for Drug Addiction

We have completed studies of the long-term effects of ibogaine treatment on patients undergoing therapy at independent ibogaine treatment centers in Mexico and New Zealand.

Ayahuasca-Assisted Treatment

MAPS supports research into the safety and effectiveness of ayahuasca-assisted treatment for drug addiction and PTSD. We also support conferences, meetings, and publications about the scientific, therapeutic, sustainable, and spiritual uses of ayahuasca.

Medical Marijuana

MAPS has completed the first-ever clinical trial of smoked marijuana for symptoms of posttraumatic stress disorder (PTSD) in veterans of war.